Nanocapsule technology: A review

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 19, Issue 2, 2002, Pages 99-134

  Couvreur, Patrick ^a   Barratt, Gillian ^a   Fattal, Elias ^a   Legrand, Philippe ^a   Vauthier, Christine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Drug targeting; Interfacial polymerization; Nanocapsules; Nanodeposition; Solvent evaporation

Indexed keywords

2 PROPANOL; ACETONE; ACETONITRILE; ALCOHOL; BENZYL BENZOATE; BETAXOLOL; BUCRILATE; BUTANOL; CALCITONIN; DRUG CARRIER; ENBUCRILATE; ETHYL CYANOACRYLATE E; GANCICLOVIR; INSULIN; IODINATED POPPYSEED OIL; ISOHEXYL CYANOACRYLATE; MIGLYOL; MONOMER; NANOCAPSULE; OCTREOTIDE; PILOCARPINE; POLOXAMER; POLOXAMER 238; POLYMER; POLYSORBATE 80; SOLVENT; SURFACTANT; TRITON X 100; TYLOXAPOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER OIL CREAM;

AQUEOUS SOLUTION; CANCER; COLLOID; DRUG ADMINISTRATION ROUTE; DRUG TARGETING; EVAPORATION; INFECTION; POLYMERIZATION; REVIEW; TECHNOLOGY;

EID: 0036388590     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i2.10     Document Type: Review

References (122)

1. Rollot JM, Couvreur P, Roblot-Treupel L, Puisieux F. Physicochemical and morphological characterization of polyisobutyl cyanoacrylate nanocapsules. J Pharm Sci 1986; 75:361.
2. Chouinard F, Kan FW, Leroux JC, Foucher C, Lenaerts V. Preparation and purification of polyisohexylcyanoacrylate nanocapsules. Int J Pharm 1991; 72:211.
3. Fresta M, Cavallaro G, Giammona G, Wehrli E, Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 1996; 17:751.
4. Ammoury N, Fessi H, Devissaguet JP, Puisieux F, Benita S. Physicochemical characterization of polymeric nanocapsules and in vitro release evaluation of indomethacin as a drug model. STP Pharmacol 1989; 5:642.
5. Aboubakar M, Couvreur P, Pinto-Alphandary H, Gouritin B, Lacour B, Farinotti R et al. Insulin-loaded nanocapsules for oral administration: In vitro and in vivo investigation. Drug Dev Res 2000; 49:109.
6. Pinto-Alphandary H, Aboubakar M Jaillard D, Couvreur P, Vauthier C. Visualization of insulin-loaded nanocapsules: In vitro characterization and in vivo study after oral administration to rats. Submitted for publication, 2001.
7. Damgé C, Aprahamiam M, Balboni G, Hoeltzel A, Andrieu V, Devissaguet JP. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int J Pharm 1987; 36:121.
8. Aprahamiam M, Michel C, Humbert W, Devissaguet JP, Damgé C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 1987; 61:69.
9. Damgé C, Michel C, Aprahamiam M, Couvreur P, Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J Controlled Release 1990; 13:233.
10. Quintanar-Guerrero D, Allemann E, Doelker E, Fessi H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm Res 1998; 15:1056.
11. Chouinard F, Buczkowski S, Lenaerts V. Poly(alkylcyanoacrylate) nanocapsules: Physicochemical characterization and mechanism of formation. Pharm Res 1994; 11:869.
12. Wohlgemuth M, Mächtle W, Mayer C. Improved preparation and physical studies of polybutylcyanoacrylate nanocapsules. J Microencapsulation 2000; 17:437.
13. Vauthier C, Schmidt C, Couvreur P. Measurement of the density of polymeric nanoparticulate drug carriers by isopycnic centrifugation. J Nanoparticle Res 1999; 1:411.
14. Barratt G. Characterization of colloidal drug carrier systems with zeta potential measurements. Pharmacol Tech Eur 1999; 11: 25.
15. Aboubakar M, Puisieux F, Couvreur P, Deyme M, Vauthier C. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J Biomed Mater Res 1999; 47:568.
16. Fattal E, Peracchia MT, Couvreur P. Poly(alkylcyanoacrylate) In: Domb AJ, Kost J, Wiseman DM, editors. Handbook of biodegradable polymers. Amsterdam: Harwood Academic Publishers, 1997.
17. Al Khouri N, Fessi H, Roblot-Treupel L, Devissaguet JP, Puisieux F. An original procedure for preparing nanocapsules of polyalkyl-cyanoacrylates for interfacial polymerization. Pharm Acta Helv 1986; 61:274.
18. Al Khouri Fallouh N, Roblot-Treupel L, Fessi H, Devissaguet JP, Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 1986; 28:125.
19. Gallardo MM, Couarraze G, Denizot B, Treupel L, Couvreur P, Puisieux F. Preparation and purification of isohexylcyanoacrylate nanocapsules. Int J Pharm 1993; 100:55.
20. Puglisi G, Fresta M, Giammona G, Venture CA. Influence of the preparation conditions in poly(ethylcyanoacrylate) nanocapsules formation. Int J Pharm 1995; 125: 283.
21. Gürsoy A, Eroglu L, Ulutin S, Tasyürek M, Fessi H, Puisieux F, Devissaguet JP. Evaluation of indomethacin nanocapsules for their physical stability and inhibitory activity on inflammation and platelet aggregation. Int J Pharm 1989; 52:101.
22. El-Samaligy MS, Rojanasakul Y, Charlton JF, Weinstein GW, Lim JK. Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit's eye. Drug Delivery 1996; 3:93.
23. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: Polyisobutylcyanoacrylate, polylactic-co-glycolic acid, poly-epsilon-caprolactone. STP Pharm Sci 1992; 2:98.
24. Desai SD, Blanchard J Pluronic® F127-based ocular delivery systems containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Deliv J Deliv Targeting Therapeutic Agents 2000; 7:201.
25. Damgé C, Michel C, Aprahamiam M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37:246.
26. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: Protection against proteases and effect in intestinal absorption in rats. J Pharm Pharmacol 1994; 46:547.
27. Damgé C, Vonderscher J, Marbach P, Pinget M. Poly(alkylcyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J Pharm Pharmacol 1997; 49:949.
28. Damgé C, Vranckx H, Baldschmidt P, Couvreur P. Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86:1403.
29. Michel C, Aprahamiam M, Defontaine L, Couvreur P, Damgé C. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharm Pharmacol 1991; 43:1.
30. Damgé C, Hillaire-Buys D, Puech R, Hoelizel A, Michel C, Ribes G. Effects of orally administered insulin nanocapsules to normal and diabetic dogs. Diabetes Nutr Metab 1995; 8:3.
31. Roques M, Damgé C, Michel C, Staedel C, Cremel G, Hubert P. Encapsulation of insulin for oral administration preserves interaction of the hormone with its receptor in vitro. Diabetes 1992; 41:451.
32. Ammoury N, Fessi H, Devissaguet JP, Allix M, Plotkine M, Boulu RG. Effect on cerebral blood flow of orally administered indomethacin-loaded poly(isobutylcyanoacrylate) and poly(D,L-lactide) nanocapsules. J Pharm Pharmacol 1990; 42:558.
33. Ammoury N, Fessi H, Devissaguet JP, Dubrasquet M, Benita S. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(D,L-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res 1991; 8:101.
34. Sai P, Damgé C, Rivereau AS, Hoeltzel A, Gouin E. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. J Autoimmunity 1996; 9:713.
35. Langer K, Zimmer A, Kreuter J Acrylic nanoparticles for ocular drug delivery. STP Pharm Sci 1997; 7:445.
36. Legrand P, Barratt G, Mosqueira V, Fessi H, Devissaguet JP. Polymeric nanocapsules as drug delivery systems, a review. STP Pharm Sci 1999; 9:411.
37. Storm G, Belloit SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Del Rev 1995; 17:31.
38. Kreuter J Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev 2001; 47:65.
39. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res 2000; 17:707.
40. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int J Pharm. 2001; 214:13.
41. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Auclair C, Couvreur P. EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. BBRC 2000; 279:401.
42. Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 1992; 9:441.
43. Nakada Y, Fattal E, Foulquier M, Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res 1996; 13:38.
44. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239.
45. Monteith DK, Levin AA. Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 1999; 27:8.
46. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: Questions of specificity. Biotechnology 1996; 14:47.
47. Vrankx H, Demoustier M, Deleers M, A new nanocapsule formulation with hydrophilic core: application to the oral administration of salmon calcitonin in rats. Eur J Pharm Biopharm. 1996; 42:345.
48. Grangier JL, Puygrenier M, Gauthier JC, Couvreur P. Nanoparticles as carriers for growth hormone releasing factor (GRF). J Controlled Release 1991; 15:3.
49. Fessi H, Devissaguet JP, Puisieux F. Procédé de préparation des systèmes colloïdaux dispersibles d'une substance sous forme de nanocapsules. French Patent Application No. 8618444; 1986.
50. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial deposition following solvent displacement. Int J Pharm 1989; 55:R1-4.
51. Quintanar-Guerrero D, Fessi H, Doelker E, Allemann E. Procédé de préparation de nanocapsules de type vésiculaire utilisable notamment comme vecteurs colloïdaux de principes actifs pharmaceutiques ou autres, French Patent 97.09.672; 1997.
52. Auvillain M, Cave G, Fessi H, Devissaguet JP. Lyophilisation de vecteurs colloïdaux submicroniques. STP Pharmacol 1989; 5:738.
53. De Chasteigner S, Fessi H, Cave G, Devissaguet JP, Puisieux F. Gastrointestinal tolerance study of a freeze-dried oral dosage form of indomethacin-loaded nanocapsules. STP Pharm Sci 1995; 5:242.
54. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polymer Sci 1997; 275:46.
55. Muller CR, Bassani VL, Pohlmann AR, Michalowski CB, Petrovick PR, Guterres SS. Preparation and characterization of spray-dried polymeric nanocapsules. Drug Dev Ind Pharm 2000; 26:343.
56. Mosqueira VCF, Legrand P, Pinto-Alphandary H, Puisieux: F, Barratt G. Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties, J Pharm Sci 2000; 89:614.
57. Magalhaes NS, Fessi H, Puisieux F, Benita S, Seiller M. An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride. J Microencapsul 1995; 12:195.
58. Benita S, Levy MY. Submicron emulsions as colloidal drug carriers for intravenous administration: Comprehensive physicochemical characterization. J Pharm Sci 1993; 82:1069.
59. Santos-Magalhaes N, Benita S, Baszkin A. Penetration of poly(oxyethylene)-poly(oxypropylene) block copolymer surfactant into soja phospholipid monolayers. Colloids Surf A 1991; 52:195.
60. Ammoury N, Fessi H, Devissaguet JP, Puisieux F, Benita S. In vitro release kinetic pattern of indomethacin from poly(D,L-lactide) nanocapsules. J Pharm Sci 1990; 79:763.
61. Ferranti V, Marchais H, Chabenat C, Orecchioni AM, Lafont O. Primidone-loaded poly-ε-caprolactone nanocapsules: Encapsulation efficiency and in vitro release profiles. Int J Pharm 1999; 193:107.
62. Santos-Magalhaes NS, Pontes A, Pereira VM, Caetano MN. Colloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules. Int J Pharm 2000; 208:71.
63. Mosqueira VCF, Legrand P, Gref R, Barratt G. In vitro release kinetic studies of PEG-modified nanocapsules and nanospheres loaded with a lipophilic drug: Halofantrine base. Proceedings of the 26th International Symposium on Controlled Release of Bioactive Materials, 20-23 June 1999, Boston, MA; 1074-1075.
64. Heurtault B, Legrand P, Mosqueira V, Devissaguet JP, Barratt G, Bories C. In vitro antileishmanial properties of surface modified and primaquine loaded nanocapsules in Leishmania donovani intramacrophagic amastigotes. Ann Trop Med Parasitol 2001; 95:529.
65. Marchais H, Benali S, Irache JM, Tharasse-Bloch C, Lafont O, Orecchioni AM. Entrapment efficiency and initial release of phenylbutazone from nanocapsules prepared from different polyesters. Drug Dev Ind Pharm 1998; 24:883.
66. Kedzierewicz F, Thouvenot P, Monot I, Hoffman M, Maincent P. Influence of different physicochemical conditions on the release of indium oxine from nanocapsules. J Biomed Material Res 1998; 39:588.
67. Guterres SS, Fessi H, Barratt G, Puisieux F, Devissaguet JP. Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: Gastrointestinal tolerance following intravenous and oral administration. Pharm Res 1995; 12:1545.
68. Andrieu V, Fessi H, Dubrasquet M, Devissaguet JP, Puisieux F, Benita S. Pharmacokinetic evaluation of indomethacin nanocapsules. Drug Des Deliv 1989; 4:295.
69. Fawaz F, Bonini F, Guyot M, Lagueny AM, Fessi H, Devissaguet JP. Disposition and protective effect against irritation after intravenous and rectal administration of indomethacin loaded nanocapsules to rabbit. Int J Pharm 1996; 133:107.
70. Dalençon F, Amjaud Y, Lafforgue C, Derouin F, Fessi H. Atovaquone and rifabutine-loaded nanocapsules: Formulation studies. Int J Pharm 1998; 153:127.
71. Fawaz F, Bonini F, Guyot M, Lagueny AM, Fessi H, Devissaguet JP. Influence of poly(D,L-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm Res 1993; 10:750.
72. Guterres SS, Fessi H, Barratt G, Puisieux F, Devissaguet JP. Poly(D,L-lactide) nanocapsules containing diclofenac: Protection from muscular damage in rats. J Biomaterials Sci Polymer Ed 2000; 11:1347.
73. Hubert B, Atkinson J, Guerret M, Hoffman M, Devissaguet JP, Maincent P. The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm Res 1991; 8:734.
74. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001; 47:55.
75. Marchal-Heussler L, Thouvenot P, Hoffman M, Maincent P. Comparison of the biodistribution in mice of 111-indium oxine encapsulated into poly(lactic-co-glycolic)-D,L-85/15 and poly(epsilon-caprolactone) nanocapsules. J Pharm Sci 1999; 88:450.
76. Morin C, Barratt G, Fessi H, Devissaguet JP, Puisieux F. Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. Int J Immunopharmacol 1994; 16:461.
77. Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int J Immunopharmacol 1996; 18:385.
78. Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Macrophage activation by a lipophilic derivative of muramyldipeptide within nanocapsules: Investigation of the mechanism of drug delivery. J Nanoparticle Res 1999; 1:91.
79. Barratt G, Puisieux F, Yu WP, Foucher C, Fessi H, Devissaguet JP. Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. Int J Immunopharmacol 1994; 16:457.
80. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents 2000; 13:155.
81. Yu WP, Wong JP, Chang TM. Biodegradable polylactic acid nanocapsules containing ciprofloxacin: Preparation and characterization. Artif Cells Blood Subst Immob Biotech 1999; 27:263.
82. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res 1993; 10:386.
83. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 1993; 10:80.
84. Calvo P, Thomas C, Alonso MJ, Vila Jato JL, Robinson JR. Study of the mechanism of interaction of poly(e-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm 1994; 103:283.
85. Zimmer A, Kreuter J, Robinson JR. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsulation 1991; 8:497.
86. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol 1996; 48:1147.
87. Calvo P, Vila-Jato JL, Alonso MJ. Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. Biomaterials 1997; 18:1305.
88. Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm 1997; 153:41.
89. Calvo P, Sanchez A, Martinez J, Lopez Calonge MI, Pastor JC, Alonso MJ. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res 1996; 13:311.
90. Ramon JJ, Calonge M, Gomez S, Lopez MI, Calvo P, Herreras JM, Alonso MJ. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr Eye Res 1998; 17:39.
91. Le Bourlais CA, Chevanne F, Turlin B, Acar L, Zia H, Sado PA et al. Effect of cyclosporin A formulations on bovine corneal absorption: Ex vivo study. J Microencap 1997; 14:457.
92. Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 1998; 32:139.
93. Jeon SI, Lee JH, Andrade JD, De Gennes PG. Protein-surface interactions in the presence of polyethylene oxide. I Simplified theory. J Colloid Interf Sci 1991; 142:149.
94. Gabizon A, Catane R, Uziely B, Kaufman B, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res 1994; 54:987.
95. Allen TM, Lopez de Menezes D, Hansen CB, Moase EH. Stealth™ liposomes for the targeting of drugs in cancer therapy. In: Gregoriadis G, McCormack B, editors. Targeting of drugs 6: Strategies for stealth therapeutic systems. New York, London: Plenum Press, 1998.
96. Dunn SE, Coombes AGA, Garnett MC, Davis SS, Davies MC, Illum L. In vitro interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J Controlled Release 1997; 44:65.
97. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnish S et al. "Stealth" corecorona nanoparticles surface modified by polyethylene glycol (PEG): Influence of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Coll Surf B Biointerfaces 2000; 18:301.
98. Mosqueira VCF, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001; 22:2967.
99. Mosqueira VCF, Legrand P, Gref R, Heurtault B, Appel M, Barratt G. Interactions between a macrophage cell line (J774A1) and surface-modified poly(D,L-lactide) nanocapsules bearing poly(ethylene glycol). J Drug Target 1999; 7:65.
100. Mosqueira VCF, Legrand P, Morgat JL, Vert M, Mysiakine E, Gref R et al. Biodistribution of novel long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res 2001; 18:1411.
101. Mosqueira VCF, Legrand P, Bories C, Devissaguet JP, Barratt G. Comparative pharmacokinetics and in vivo efficacy of an intravenous formulation of halofantrine in long-circulating nanocapsules in Plasmodium beighei-infected mice. Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials, 7-13 July 2000, Paris, France; 490-491.
102. Chang TM, D'Agnillo F, Yu WP, Razack S. Two future generations of blood substitutes based on polyhemoglobin-SOD-catalase and nanoencapsulation. Adv Drug Deliv Rev 2000;40:213.
103. Bourdon O, Mosqueira V, Legrand P, Blais J. A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorine encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells. J Photochem Photobiol B 2000; 55:164.
104. Blanco-Prieto M.J, Delie F, Fattal E, Tartar A, Puisieux F, Gulik A, Couvreur P. Characterization of V3 BRU peptide-loaded small PLGA microspheres prepare by a (w1/o)w2 emulsion solvent evaporation method. Int J Pharm 1994; 111:137.
105. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull 1988; 36:1095.
106. Jeffery H, Davis SS, O'Hagan DT. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil-in-water) emulsion solvent evaporation technique. Pharm Res 1993; 10:362.
107. Blanco-Prieto MJ, Leo E, Delie F, Gulik A, Couvreur P, Fattal E. Study of the influence of several stabilizing agents on the entrapment and in vitro release of pBC 264 from poly(lactide-co-glycolide) microspheres prepared by a W/O/W solvent evaporation method. Pharm Res 1996; 13:1127.
108. Rojas J, Pinto-Alphandary H, Leo E, Pecquet S, Couvreur P, Fattal E. Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly(D,L-lactide-co-glycolide) microspheres. Int J Pharm 1999; 183:67.
109. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski R, Levy RJ. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Controlled Release 1997; 43:197.
110. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. EurJ Pharm Biopharm 1997; 43:287.
111. Lamprecht A, Ubrich N, Hombreiro Perez M, Lehr C, Hoffman M, Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 1999; 184:97.
112. Lamprecht A, Ubrich N, Hombreiro Perez M, Lehr C, Hoffman M, Maincent P. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm 2000; 196:177.
113. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Controlled Release 1998; 50:31.
114. Gasper MM, Blanco D, Cruz ME, Alonso MJ. Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J Controlled Release 1998; 52:53.
115. Zambaux MF, Bonneaux F, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C-loaded PLA nanoparticles. J Controlled Release 1999; 60:179.
116. Nicoli S, Santi P, Couvreur P, Couarraze G, Colombo P, Fattal E. Design oftriptorelin loaded nanospheres for transdermal iontophoretic administration. Int J Pharm 2001; 214:31.
117. Lemoine D, Preat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J Controlled Release 1998; 54:15.
118. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. Int J Pharm 2001; 212:1.
119. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W et al. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J Controlled Release 2001; 71:203.
120. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998; 15:270.
121. Das SK, Miller KJ, Chattaraj SC. Facilitated delivery of oligonucleotide as inhibitor of serotonin uptake. In: Proceedings of the 25th International Symposium on Controlled Release Bioactive Materials, June 21-24, 1998, Las Vegas, NV.
122. Delie F, Berton M, Allemann E, Gurny R. Comparison of two methods of encapsulation of an oligonucleotide into poly(D,L-lactic acid) particles. Int J Pharm 2001; 214:25.